… Extracorporeal photopheresis (ECP) has been in clinical use for over three decades after
receiving FDA approval for the palliative treatment of the Sézary Syndrome variant of …

… Extracorporeal photochemotherapy as an effective treatment modality in chronic graft-versus-host
disease. J Eur Acad Dermatol Venereol 1996; 7: 155–162. 14 Dall’Amico R, Rossetti F…

… Extracorporeal photopheresis (ECP) was initially developed for use in cutaneous T-cell
lymphoma (CTCL), and is now available at more than 200 centers worldwide. After the …

… host disease (GvHD), which is a key cause of morbidity and mortality to patients following
allogeneic HSCT (2), where control of GvHD is central to optimizing long-term outcomes. The …

Abstract: Photopheresis (extracorporeal photochemotherapy, ECP) is a new type of
photochemotherapy used for the treatment of oncological and autoimmune diseases. Additionally, …

… Extracorporeal photopheresis (ECP, also known as extracorporeal photochemotherapy,
extracorporeal photoimmunotherapy or just photopheresis) is a leukapheresis-based therapy …

… Extracorporeal photopheresis (ECP) exposes isolated white blood cells to photoactivatable
… recently, immune-mediated diseases such as graft-versus-host disease (GVHD), the major …

… Combined therapy of the Sezary syndrome with extracorporeal photochemotherapy and low
dose … of resistant chronic graft versus host disease with extracorporeal photopheresis using …

… Extracorporeal photopheresis (ECP) is a method of manipulating white blood cells (WBCs)
external to the body in a way that, when they are reinfused to the patient, causes down-…

… Extracorporeal photopheresis (ECP) was given to 23 patients with steroid-refractory acute
GVHD (aGVHD, grade II (n=10), III (n=7) or IV (n=6)). The median duration of ECP was 7 …